There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Illumina (ILMN – Research Report) and Humana (HUM – Research Report) with bullish sentiments.
Illumina (ILMN)
Leerink Partners analyst Puneet Souda maintained a Buy rating on Illumina on April 1. The company’s shares closed last Wednesday at $127.74.
According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $152.00.
See today’s best-performing stocks on TipRanks >>
Humana (HUM)
Leerink Partners analyst Whit Mayo maintained a Buy rating on Humana on April 1 and set a price target of $400.00. The company’s shares closed last Wednesday at $308.06, close to its 52-week low of $299.23.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
Humana has an analyst consensus of Moderate Buy, with a price target consensus of $397.60, which is a 30.0% upside from current levels. In a report issued on April 2, TD Cowen also maintained a Buy rating on the stock with a $396.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ILMN:
- Early notable gainers among liquid option names on March 21st
- EU opinion could mean Illumina no longer required to fund GRAIL, says Guggenheim
- Illumina downgraded to Mixed from Positive view at OTR Global
- Early notable gainers among liquid option names on March 19th
- China stimulus positive for GE HealthCare, tool companies, says Evercore ISI
